2010 drug utilization and cost trends for antidiabetic agents

American Journal of Pharmacy Benefits

Volumn 3, Issue 1, 2011, Pages 54-61

  Theodorou, Anna A ^a   Johnson, Kelly M ^a   Ward, Mark W ^a   Szychowski, John A ^a  

^a CVS Caremark   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; BIGUANIDE DERIVATIVE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLIBENCLAMIDE; GLIBENCLAMIDE PLUS METFORMIN; GLIMEPIRIDE; GLIPIZIDE; HEMOGLOBIN A1C; INSULIN; INSULIN SENSITIZING AGENT; METFORMIN; METFORMIN PLUS ROSIGLITAZONE; PIOGLITAZONE; PRAMLINTIDE; ROSIGLITAZONE; SITAGLIPTIN; SULFONYLUREA DERIVATIVE;

ARTICLE; COMBINATION CHEMOTHERAPY; DIABETES MELLITUS; DRUG COST; DRUG RELEASE; DRUG UTILIZATION; HUMAN; HYPERGLYCEMIA; INSULIN RESISTANCE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; TREND STUDY; WEIGHT CHANGE;

EID: 79951486100     PISSN: 19454481     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Huang ES, Basu A, O'Grady M, Capretta JC. Projecting the future diabetes population size and related costs for the U.S. Diabetes Care. 2009;32(12): 2225-2229.
2. Agency for Healthcare Research and Quality. Diabetes disparities among racial and ethnic minorities. Fact sheet. http://www.ahrq.gov/research/diabdisp.htm#2. Accessed October 22, 2010.
3. American Diabetes Association. Health Care Reform and People With and at-Risk for Diabetes. http://main.diabetes.org/site/DocServer/HCR_People_with_Diabetes.pdf?docID=49641. Accessed October 22, 2010.
4. American Diabetes Association. Diabetes statistics. Diabetes Basics. http://www.diabetes.org/diabetes-basics/diabetes-statistics. Accessed September 20, 2010.
5. National Diabetes Information Clearinghouse. National diabetes statistics, 2007. http://diabetes.niddk.nih.gov/dm/pubs/statistics/#people. Accessed October 22, 2010.
6. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control [published correction appears in Endocr Pract. 2009;15(7):768-770]. Endocr Pract. 2009;15(6):542-543.
7. Food and Drug Administration. FDA significantly restricts access to the diabetes drug Avandia. FDA news release. September 23, 2010. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm226956.htm. Accessed October 7, 2010.
8. Theodorou AA, Szychowski JA, Slezak J, Fox SM. Generational impact on prescription drug trend: part 1. Am J Pharm Benefits. 2009;1(2):111-115.
9. Theodorou AA, Szychowski JA, Slezak J, Fox SM. Generational impact on prescription drug trend: part 2. Am J Pharm Benefits. 2009;1(3):165-173.
10. Teva announces final approval of lovastatin tablets. Business Wire. December 17, 2001.
11. Phelps K. Teva foresees sustained growth despite slow start to fiscal 2006. The Pink Sheet. February 22, 2007;18(90 No. 005).
12. Phelps K. Teva and Ranbaxy launch generic Zocor with 180-day exclusivity. The Pink Sheet Daily. June 23, 2010.
13. Food and Drug Administration. FDA issues safety alert on Avandia. FDA news release. May 21, 2007. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm108917.htm. Accessed September 20, 2010.
14. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes [published correction appears in N Engl J Med. 2007;357(1):100]. N Engl J Med. 2007;356(24):2457-2471.
15. Marson B. Avandia and Actos add 'black boxes' for heart failure. The Pink Sheet. August 20, 2007;69(34).
16. Merrill J. Avandia revenues sink under safety attack. The Pink Sheet. July 25, 2007;19(143).
17. Mundy A, Favole J. Study ties diabetes drug to fractures. The Wall Street Journal. June 8, 2009.